NEW YORK (GenomeWeb) – Myriad Genetics said this week that James Evans will retire as its CFO "in order to attend to family health issues." Evans will continue to perform his duties until a replacement is found. Myriad said it will hire an executive search firm to identify candidates for consideration.

Evans joined Myriad in 1995 as corporate controller and was promoted to VP of finance in July 2005. He became CFO in November 2007. Evans played a leading role in Myriad's acquisitions of Rules-Based Medicine and Crescendo Biosciences.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.